PTH and hyperphosphatemia: With the expansion of use, it is estimated that half of the patients who use oral calcitriol would be indicated for paricalcitol because they persist with PTH levels above 300 pg/mL, in the absence of hypercalcemia and hyperphosphatemia, increasing to 23% of patients on dialysis the use of paricalcitol.